US4064232A - Process for isolating the immunogenic components of influenza viruses - Google Patents

Process for isolating the immunogenic components of influenza viruses Download PDF

Info

Publication number
US4064232A
US4064232A US05/687,453 US68745376A US4064232A US 4064232 A US4064232 A US 4064232A US 68745376 A US68745376 A US 68745376A US 4064232 A US4064232 A US 4064232A
Authority
US
United States
Prior art keywords
cationic detergent
signifies
virus
detergent
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/687,453
Inventor
Helmut Bachmayer
Gerhard Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DUPHAR BV
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH44774A external-priority patent/CH589453A5/xx
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to US05/836,015 priority Critical patent/US4140762A/en
Application granted granted Critical
Publication of US4064232A publication Critical patent/US4064232A/en
Assigned to DUPHAR B.V. reassignment DUPHAR B.V. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: FIDELITY UNION BANK
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • influenza vaccines in particular influenza sub-unit vaccines, and their production by selective solubilisation and isolation of the immunogenic components of influenza virus.
  • FIG. 1 is a schematic representation of the influenza virus particle.
  • the genetic material, ribonucleic acid (RNA), associated with the group-specific nucleoprotein is surrounded by a double membrane consisting of an inner layer of protein and an outer layer of host-derived lipid material.
  • the two glycoproteins are the major immunogenic components of the influenza virus, all other components, including other virus proteins, nucleic acid and lipids, being non-essential for the induction of immunity.
  • the presence of such non-essential materials in an influenza vaccine may lead to undesired side effects and, in any effect, limits the dosage of the vaccine which can be administered and, consequently, the level of immunity which can be achieved.
  • influenza vaccine should, therefore, contain the two essential immunogens, hemagglutinin and neuraminidase, in the absence or substantial absence of non-essential components of the viral particle.
  • Previous attempts to separate the influenza immunogens have involved as an initial step, substantially complete disruption or solubilisation of the virus particle, for example with anionic detergents, such as sodium desoxycholate or sodium dodecyl sulphate, such that all or the major portion of the viral components are liberated and go into solution with the immunogens.
  • anionic detergents such as sodium desoxycholate or sodium dodecyl sulphate
  • the present invention provides a method for isolating the hemagglutinin and neuraminidase immunogens, involving selectively solubilising these components while leaving residual subviral particles consisting of the intact lipid/protein membrane enclosing all other non-essential viral components.
  • the difference in size or density of the solubilised immunogens and the residual sub-viral particles permits ready separation of the immunogens by conventional separating methods utilising such differences in physical properties.
  • the present invention accordingly provides a method of isolating the hemgagglutinin and neuraminidase components from influenza virus, comprising treating influenza virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles.
  • the method of invention may suitably be applied to influenza Tupe A, A1, A2 or B viruses or mixtures thereof.
  • the particular strain employed will, of course depend on the immunity desired from the immunogens to be isolated but the following may be mentioned as examples: strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (" Mutagrip", Institut Pasteur) and B/Mass/67.
  • the influenza virus to be treated is suitably multiplied in conventional manner, for example by inoculation in 11 day old embryonated chicken eggs, and incubation for a suitable period at a suitable temperature, for example for 2 days at 37° C.
  • the harvested allantoic fluids ae then suitably pooled and the virus suitably concentrated and purified by ultracentrifugation followed by resuspension of the virus in, for example, phosphate buffered physiological saline, or by centrifuging in a continuous flow zonal centrifuge using, for example, a sucrose gradient in phosphate buffered physiological saline, followed by lowering of the sucrose content to, for example, less than 5%, suitably by dialysis against physiological saline, or by Sephadex chromatography or diluting.
  • concentration of the starting virus is not critical and can be adjusted depending on the desired yield of immunogens.
  • the pH of the virus concentrate is suitably from 6.5 to 8.5, using buffers, such as phosphate buffer, where required, prior to the addition of the cationic detergent, and the concentrate may also be inactivated, e.g. by the addition of formaldehyde.
  • the cationic detergent is then suitably added to the virus concentrate in the form of an aqueous solution.
  • the appropriate quantity of cationic detergent to be added will depend, for example on the particular detergent employed. However, in general, the cationic detergent is suitably added in such a quantity that the weight ratio of detergent to protein in the resulting mixture is from 1:2 to 1:10, particularly from 1:3 to 1:5.
  • the mixture is suitably allowed to stnad, for example for a period of 30 minutes to 16 hours at a temperature of, for example 4° C to 37° C, the higher temperatures requiring the shorter standing times.
  • the mixture is allowed to stand for 30 to 60 minutes at room temperature, or overnight at 4° C.
  • the cationic detergent employed may be any cationic detergent sufficiently active to solubilise the hemagglutinin and neuraminidase components, but insufficiently active, under the conditions employed, to disrupt the whole virus particle.
  • Such cationic detergents may be selected from the well-known class of formula I, ##STR1## in which R 4 signifies alkyl or aryl,
  • R 1 , r 2 and R 3 are the same or different and each signifies alkyl or aryl, or
  • R 1 and R 2 together with the nitrogen atom to which they are attached to form a 5- or 6-membered saturated heterocyclic ring, and R 3 signifies alkyl or aryl, or
  • R 1 , r 2 and R 3 together with the nitrogen atom to which they are attached, signify a 5- or 6-membered heterocyclic ring, unsaturated at the nitrogen atom, and
  • X signifies an anion
  • Representative compounds of formula I include those of formula Ia, ##STR2## in which X is as defined above, and
  • R 4 ' signifies alkyl of 8 to 22 carbon atoms, and either
  • R 1 ' and R 2 ' are the same or different and each signifies methyl or alkyl of 8 to 22 carbon atoms, or
  • R 1 ' signifies methyl and R 2 ' signifies benzyl
  • R 4 signifies alkyl of 12 to 18 carbon atoms
  • R 5 signifies hydrogen or methyl, preferably hydrogen.
  • Preferred alkyl radicals of 8 to 22 carbon atoms contain 12 to 18 carbon atoms.
  • Preferred alkyl radicals of 12 to 18 carbon atoms include lauryl, myristyl, cetyl and stearyl.
  • X preferably signifies such anions as chloride, bromide, sulphate, or acetate, particularly chloride or bromide.
  • the preferred compounds of formula Iaa include myristyltrimethylammonium and cetyltrimethylammonium salts, in particular chloride or bromide, more particularly bromides.
  • Preferred compounds of formula Iab include stearyldimethylbenzylammonium salts, in particular chloride or bromide, more particularly bromide.
  • the preferred compounds of formula Ib include cetylpyridinium salts, in particular chloride or bromide, more particularly bromide.
  • cationic detergents which may suitably be employed include benzalkonium chlorides and bromides, for example benzethonium chloride or methylbenzenethonium chloride, as well as such agents as decamethonium chloride.
  • the preferred cationic detergent for use in the process of the invention is cetyltrimethylammonium bromide.
  • the hemagglutinin and neuraminidase components may be separated from residual intact sub-viral particles using conventional methods for the separation of materials having different sizes or density, for example by gradient centrifuging, using sucrose or sodium glutamate media, followed by fractionation of the gradients, by sedimentation, by molecular sieve chromatography or by pelleting in an ultracentrifuge.
  • the mixture of immunogens produced in accordance with the process of the invention are suitable for use in influenza vaccines.
  • the hemagglutinin and neuraminidase components isolated as described above are suitably resuspended in a conventional diluent, for example a physiological isotonic solution, e.g. a 0.9% sodium chloride solution, optionally buffered, e.g. with phosphate buffer.
  • a physiological isotonic solution e.g. a 0.9% sodium chloride solution
  • optionally buffered e.g. with phosphate buffer.
  • Sucrose remaining from the purification of the initial virus or from the separation of the solubilised components should suitably be reduced to less than 5% by weight in the vaccine, for example by dialysis.
  • the content of cationic detergent remaining should largely be removed, for example reduced to less than 0.01% in the vaccine, for example by dialysis or gel chromatography.
  • preserving agents or inactivating agents such as formaldehyde
  • inactivating agents such as formaldehyde
  • Immunogenicity of the vaccines of the invention may also suitably be improved by inclusion of conventional immunological adjuvants, such as aluminium hydroxide or aluminium phosphate, in conventional amounts, for example, by inclusion of 0.2% of aluminium hydroxide.
  • conventional immunological adjuvants such as aluminium hydroxide or aluminium phosphate
  • the vaccines produced in accordance with the invention are useful as vaccines against influenza viruses, for example those mentioned above, as shown, for example, by comparison with whole virus vaccines, having the same immunogenic content, in the mouse protection test.
  • Separate groups of 30 mice are administered, i.p., 0.25 ml of whole virus vaccine and sub-unit vaccine of the invention, each having a hemagglutinin content of about 2 8 .
  • Separate groups are infected, 3,4 and 8 weeks after immunisation, with a virulent virus by spray application.
  • On the ninth day after infection the protection against mortality and against lung lesions is evaluated in each group.
  • the test is repeated using different antigenic contents in the vaccines.
  • the results indicate that the sub-unit vaccines of the invention produce a more prolonged immunity against the infecting virus but otherwise parallel effects to the whole virus vaccine.
  • the dosage to be administered will, of course, vary. However, in general, satisfactory results are obtained when administered at a single dose of from about 9 to 43 international units per kg of animal body weight. For the larger mammals, a single dose of from 600 to 3000 internaitonal units is indicated.
  • the dosage is suitably administered sub-cutaneously or intramuscularly.
  • Influenza virus of the antigen type X-31 (recombination of the strain A 2 /Aichi/68) is multiplied in embryonated chicken eggs by incubation at 37° C for two days. The eggs are then chilled at 4° C overnight and the harvested infected allantoic fluid pooled. The virus is subsequently concentrated and purified from the infected allantoic liquid by centrifuging in a continuous flow zonal centrifuge (model RK, Electro-Nucleonics) using a sucrose gradient in phosphate buffered saline.
  • the immunogens are split off by adding to the virus suspension 1/50 of its volume of an aqueous detergent solution (cetyltrimethylammonium bromide, 1% solution). After 30 to 60 minutes (room temperature) the reaction mixture is worked up by zonal gradient centrifuging using a preformed linear sucrose gradient and subsequent fractionation of the gradients with a peristaltic pump. Hemagglutinin and neuraminidase are solubilized quantitatively and are present in the upper part of the gradient, well separated from the virus residual particle which forms a sediment much more rapidly.
  • Multiplication, concentration and cleavage of the virus are effected as described in Example 1.
  • Working up is effected by equilibrium centrifuging in a preformed sucrose gradient. After adjusting equilibrium, the gradient is fractionated and tested: hemagglutinin and neuraminidase are present in the lighter part of the gradient, well separated from the more dense virus residual particle.
  • the process is effected as described in Example 1 or 2, except that influenza strain MRC-2 (recombination of type A 2 /England/42/72) or MRC-11 (recombination of type A 2 /Port Chalmers/73) is used.
  • the process is effected as described in Example 1 or 3, except that the reaction mixture is worked up by molecular sieve chromatography.
  • aqueous solution 0.5%) of cetylpyridinium bromide is added to influenza virus of the type A/Pasteur/30 C ("Mutagrip", Institut Pasteur) which has been inactivated with formol, up to a final concentration of 0.02 to 0.1%.
  • Working up is effected in a manner analogous to that described in Example 1, 2 or 4.
  • the process is effected as described in Example 1, 2, 4 or 5, except that the influenza strain B/Mass/67 is used.
  • the process is effected as described in Example 1, 3, 5 or 6, except that the cleavage mixture is worked up by pelleting in an ultra-centrifuge. This may, for example, be effected in a Beckmann L-2-65 B centrifuge (rotor 60 Ti, 35 000 r.p.m., 90 minutes). The solubilzed immunogens are present in the supernatant fraction.
  • influenza vaccine of the invention may be formulated as follows:
  • Phosphate buffer in 0.9% physiological saline to 0.5 ml.
  • the immunogenic mixture may be produced in accordance with any one of the preceding Examples, for example that produced in Example 3 from the influenza strain MRC-11 (recombination of type A2/Port Chalmers /73).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The immunogenic components from influenze viruses are isolated by selectively solubilizing the component in an aqueous media with a cationic detergent.

Description

This is a continuation of application Ser. No. 539,349 filed Jan. 8, 1975 now abandoned.
The present invention relates to influenza vaccines, in particular influenza sub-unit vaccines, and their production by selective solubilisation and isolation of the immunogenic components of influenza virus.
FIG. 1 is a schematic representation of the influenza virus particle. The genetic material, ribonucleic acid (RNA), associated with the group-specific nucleoprotein is surrounded by a double membrane consisting of an inner layer of protein and an outer layer of host-derived lipid material. Two glycoproteins, hemagglutinin and neuraminidase, appear as projections or spikes on the surface of the viral envelope.
It is now well-established that the two glycoproteins, hemagglutinin and neuraminidase, are the major immunogenic components of the influenza virus, all other components, including other virus proteins, nucleic acid and lipids, being non-essential for the induction of immunity. However, the presence of such non-essential materials in an influenza vaccine may lead to undesired side effects and, in any effect, limits the dosage of the vaccine which can be administered and, consequently, the level of immunity which can be achieved.
The ideal influenza vaccine should, therefore, contain the two essential immunogens, hemagglutinin and neuraminidase, in the absence or substantial absence of non-essential components of the viral particle. Previous attempts to separate the influenza immunogens have involved as an initial step, substantially complete disruption or solubilisation of the virus particle, for example with anionic detergents, such as sodium desoxycholate or sodium dodecyl sulphate, such that all or the major portion of the viral components are liberated and go into solution with the immunogens. A subsequent purification or partial purification of the desired immunogens is necessary, and is very elaborate and laborious and the yields are usually low.
The present invention provides a method for isolating the hemagglutinin and neuraminidase immunogens, involving selectively solubilising these components while leaving residual subviral particles consisting of the intact lipid/protein membrane enclosing all other non-essential viral components. The difference in size or density of the solubilised immunogens and the residual sub-viral particles permits ready separation of the immunogens by conventional separating methods utilising such differences in physical properties.
It has thus been found that such selective solubilisation of the hemagglutinin and neuraminidase components can be achieved by treatment of the influenza virus with a cationic detergent.
The present invention accordingly provides a method of isolating the hemgagglutinin and neuraminidase components from influenza virus, comprising treating influenza virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles.
The method of invention may suitably be applied to influenza Tupe A, A1, A2 or B viruses or mixtures thereof. The particular strain employed will, of course depend on the immunity desired from the immunogens to be isolated but the following may be mentioned as examples: strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (" Mutagrip", Institut Pasteur) and B/Mass/67.
The influenza virus to be treated is suitably multiplied in conventional manner, for example by inoculation in 11 day old embryonated chicken eggs, and incubation for a suitable period at a suitable temperature, for example for 2 days at 37° C. The harvested allantoic fluids ae then suitably pooled and the virus suitably concentrated and purified by ultracentrifugation followed by resuspension of the virus in, for example, phosphate buffered physiological saline, or by centrifuging in a continuous flow zonal centrifuge using, for example, a sucrose gradient in phosphate buffered physiological saline, followed by lowering of the sucrose content to, for example, less than 5%, suitably by dialysis against physiological saline, or by Sephadex chromatography or diluting. The concentration of the starting virus is not critical and can be adjusted depending on the desired yield of immunogens.
The pH of the virus concentrate is suitably from 6.5 to 8.5, using buffers, such as phosphate buffer, where required, prior to the addition of the cationic detergent, and the concentrate may also be inactivated, e.g. by the addition of formaldehyde. The cationic detergent is then suitably added to the virus concentrate in the form of an aqueous solution. The appropriate quantity of cationic detergent to be added will depend, for example on the particular detergent employed. However, in general, the cationic detergent is suitably added in such a quantity that the weight ratio of detergent to protein in the resulting mixture is from 1:2 to 1:10, particularly from 1:3 to 1:5. After addition, the mixture is suitably allowed to stnad, for example for a period of 30 minutes to 16 hours at a temperature of, for example 4° C to 37° C, the higher temperatures requiring the shorter standing times. Preferably, the mixture is allowed to stand for 30 to 60 minutes at room temperature, or overnight at 4° C.
The cationic detergent employed may be any cationic detergent sufficiently active to solubilise the hemagglutinin and neuraminidase components, but insufficiently active, under the conditions employed, to disrupt the whole virus particle.
Such cationic detergents may be selected from the well-known class of formula I, ##STR1## in which R4 signifies alkyl or aryl,
R1, r2 and R3 are the same or different and each signifies alkyl or aryl, or
R1 and R2, together with the nitrogen atom to which they are attached to form a 5- or 6-membered saturated heterocyclic ring, and R3 signifies alkyl or aryl, or
R1, r2 and R3, together with the nitrogen atom to which they are attached, signify a 5- or 6-membered heterocyclic ring, unsaturated at the nitrogen atom, and
X signifies an anion.
Representative compounds of formula I include those of formula Ia, ##STR2## in which X is as defined above, and
R4 ' signifies alkyl of 8 to 22 carbon atoms, and either
R1 ' and R2 ' are the same or different and each signifies methyl or alkyl of 8 to 22 carbon atoms, or
R1 ' signifies methyl and R2 ' signifies benzyl,
in particular compounds of formula Iaa, ##STR3## in which R4 ' and X are as defined above,
or of formula Iab, ##STR4## in which R4 ' and X are as defined above.
Further representative compounds of formula I are those of formula Ib, ##STR5## in which X is as defined above,
R4 " signifies alkyl of 12 to 18 carbon atoms, and
R5 signifies hydrogen or methyl, preferably hydrogen.
Preferred alkyl radicals of 8 to 22 carbon atoms contain 12 to 18 carbon atoms. Preferred alkyl radicals of 12 to 18 carbon atoms include lauryl, myristyl, cetyl and stearyl.
In the above formulae, X preferably signifies such anions as chloride, bromide, sulphate, or acetate, particularly chloride or bromide.
The preferred compounds of formula Iaa include myristyltrimethylammonium and cetyltrimethylammonium salts, in particular chloride or bromide, more particularly bromides. Preferred compounds of formula Iab include stearyldimethylbenzylammonium salts, in particular chloride or bromide, more particularly bromide. The preferred compounds of formula Ib include cetylpyridinium salts, in particular chloride or bromide, more particularly bromide.
Other cationic detergents which may suitably be employed include benzalkonium chlorides and bromides, for example benzethonium chloride or methylbenzenethonium chloride, as well as such agents as decamethonium chloride.
The preferred cationic detergent for use in the process of the invention is cetyltrimethylammonium bromide.
Upon completion of the process, the hemagglutinin and neuraminidase components may be separated from residual intact sub-viral particles using conventional methods for the separation of materials having different sizes or density, for example by gradient centrifuging, using sucrose or sodium glutamate media, followed by fractionation of the gradients, by sedimentation, by molecular sieve chromatography or by pelleting in an ultracentrifuge.
The mixture of immunogens produced in accordance with the process of the invention are suitable for use in influenza vaccines. For this purpose, the hemagglutinin and neuraminidase components isolated as described above are suitably resuspended in a conventional diluent, for example a physiological isotonic solution, e.g. a 0.9% sodium chloride solution, optionally buffered, e.g. with phosphate buffer. Sucrose remaining from the purification of the initial virus or from the separation of the solubilised components, should suitably be reduced to less than 5% by weight in the vaccine, for example by dialysis. Likewise, the content of cationic detergent remaining should largely be removed, for example reduced to less than 0.01% in the vaccine, for example by dialysis or gel chromatography.
If desired, preserving agents or inactivating agents, such as formaldehyde, may be added to the vaccines, in conventional amounts, for example at a ratio by weight at 1 part to 10,000 parts.
Immunogenicity of the vaccines of the invention may also suitably be improved by inclusion of conventional immunological adjuvants, such as aluminium hydroxide or aluminium phosphate, in conventional amounts, for example, by inclusion of 0.2% of aluminium hydroxide.
As indicated, the vaccines produced in accordance with the invention are useful as vaccines against influenza viruses, for example those mentioned above, as shown, for example, by comparison with whole virus vaccines, having the same immunogenic content, in the mouse protection test. Separate groups of 30 mice are administered, i.p., 0.25 ml of whole virus vaccine and sub-unit vaccine of the invention, each having a hemagglutinin content of about 28. Separate groups are infected, 3,4 and 8 weeks after immunisation, with a virulent virus by spray application. On the ninth day after infection the protection against mortality and against lung lesions is evaluated in each group. The test is repeated using different antigenic contents in the vaccines. The results indicate that the sub-unit vaccines of the invention produce a more prolonged immunity against the infecting virus but otherwise parallel effects to the whole virus vaccine.
For such usage the dosage to be administered will, of course, vary. However, in general, satisfactory results are obtained when administered at a single dose of from about 9 to 43 international units per kg of animal body weight. For the larger mammals, a single dose of from 600 to 3000 internaitonal units is indicated.
The dosage is suitably administered sub-cutaneously or intramuscularly.
The following Examples illustrate the invention.
EXAMPLE 1
Influenza virus of the antigen type X-31 (recombination of the strain A2 /Aichi/68) is multiplied in embryonated chicken eggs by incubation at 37° C for two days. The eggs are then chilled at 4° C overnight and the harvested infected allantoic fluid pooled. The virus is subsequently concentrated and purified from the infected allantoic liquid by centrifuging in a continuous flow zonal centrifuge (model RK, Electro-Nucleonics) using a sucrose gradient in phosphate buffered saline. The virus concentrate obtained after reduction of the sucrose content to less than 5% by dialysis against phosphate buffered saline in the cold, has a hemagglutination titre of 1:217 and a protein content of 0.7 mg/cc. The immunogens are split off by adding to the virus suspension 1/50 of its volume of an aqueous detergent solution (cetyltrimethylammonium bromide, 1% solution). After 30 to 60 minutes (room temperature) the reaction mixture is worked up by zonal gradient centrifuging using a preformed linear sucrose gradient and subsequent fractionation of the gradients with a peristaltic pump. Hemagglutinin and neuraminidase are solubilized quantitatively and are present in the upper part of the gradient, well separated from the virus residual particle which forms a sediment much more rapidly.
EXAMPLE 2
Multiplication, concentration and cleavage of the virus are effected as described in Example 1. Working up is effected by equilibrium centrifuging in a preformed sucrose gradient. After adjusting equilibrium, the gradient is fractionated and tested: hemagglutinin and neuraminidase are present in the lighter part of the gradient, well separated from the more dense virus residual particle.
EXAMPLE 3
The process is effected as described in Example 1 or 2, except that influenza strain MRC-2 (recombination of type A2 /England/42/72) or MRC-11 (recombination of type A2 /Port Chalmers/73) is used.
EXAMPLE 4
The process is effected as described in Example 1 or 3, except that the reaction mixture is worked up by molecular sieve chromatography.
EXAMPLE 5
An aqueous solution (0.5%) of cetylpyridinium bromide is added to influenza virus of the type A/Pasteur/30 C ("Mutagrip", Institut Pasteur) which has been inactivated with formol, up to a final concentration of 0.02 to 0.1%. Working up is effected in a manner analogous to that described in Example 1, 2 or 4.
EXAMPLE 6
The process is effected as described in Example 1, 2, 4 or 5, except that the influenza strain B/Mass/67 is used.
EXAMPLE 7
The process is effected as described in Example 1, 3, 5 or 6, except that the cleavage mixture is worked up by pelleting in an ultra-centrifuge. This may, for example, be effected in a Beckmann L-2-65 B centrifuge (rotor 60 Ti, 35 000 r.p.m., 90 minutes). The solubilzed immunogens are present in the supernatant fraction.
EXAMPLE 8
The procedure of any of Examples 1 to 7 is repeated but employing, in place of the cetyltrimethylammonium bromide solution, a 1% solution of myristyltrimethylammonium bromide, benzethonium chloride, methylbenzethonium chloride, decamethonium chloride or stearyldimethylbenzylammonium bromide. Similar results are obtained.
EXAMPLE 9
An influenza vaccine of the invention may be formulated as follows:
Immunogenic mixture: 700 international units
Thiomerosal: 1 part in 10,000 parts
Phosphate buffer in 0.9% physiological saline: to 0.5 ml.
The immunogenic mixture may be produced in accordance with any one of the preceding Examples, for example that produced in Example 3 from the influenza strain MRC-11 (recombination of type A2/Port Chalmers /73).

Claims (23)

What is claimed is:
1. A method of isolating the hemagglutinin and neuramuridase components from influenza virus, comprising treating influenza virus in an aqueous medium with a cationic detergent to selectively solubilise components, and separating the resulting solubilised components from residual sub-viral particles.
2. A method according to claim 1, in which the influenza virus is an influenza Type A, A1, A2 or B virus or a mixture of any two or more thereof.
3. A method according to claim 1, in which the influenza virus is strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
4. A method according to claim 1, in which the cationic detergent is added to a virus concentrate having a pH of from 6.5 to 8.5.
5. A method according to claim 4, in which the virus concentrate is inactivated with formaldehyde prior to the addition of the cationic detergent.
6. A method according to claim 1, in which the cationic detergent is added in the form of an aqueous solution.
7. A method according to claim 1, in which the cationic detergent is added in such a quantity that the weight ratio of detergent to protein in the resulting mixture is from 1:2 to 1:10.
8. A method according to claim 7, in which the weight ratio is from 1:3 to 1:5.
9. A method according to claim 1, in which, after the addition of the cationic detergent, the resulting mixture is allowed to stand for 30 minutes to 16 hours at 4° C to 37° C.
10. A method according to claim 9, in which the mixture is allowed to stand for 30 to 60 minutes at room temperature.
11. A method according to claim 9, in which the mixture is allowed to stand overnight at 4° C.
12. A method according to claim 1, in which the cationic detergent is a compound of the formula, ##STR6## in which R4 signifies alkyl or aryl, R1, R2 and R3 are the same or different and each signifies alkyl or aryl, or
R1 and R2, together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring, and R3 signifies alkyl or aryl, or
R1, r2 and R3, together with the nitrogen atom to which they are attached, signify a 5- or 6-membered heterocyclic ring, unsaturated at the nitrogen atom, and
X signifies an anion.
13. A method according to claim 1, in which the cationic detergent is a compound of formula, ##STR7## in which X is an anion, and
R4 ' signifies alkyl of 8 to 22 carbon atoms, and either
R1 ' and R2 ' are the same or different and each signifies methyl or alkyl of 8 to 22 carbon atoms, or
R1 ' signifies methyl and R2 ' signifies benzyl.
14. A method according to claim 1, in which the cationic detergent is a compound of the formula ##STR8## in which R4 ' signifies alkyl of 8 to 22 carbon atoms and X is an anion.
15. A method according to claim 1, in which the cationic detergent is a compound of the formula ##STR9## in which R4 1 signifies alkyl of 8 to 22 carbon atoms and X is an anion.
16. A method according to claim 1, in which the cationic detergent is a compound of the formula, ##STR10## in which X is an anion,
R4 " signifies alkyl of 12 to 18 carbon atoms, and
R5 signifies hydrogen.
17. A method according to claim 1, in which the cationic detergent is a myristyltrimethylammonium or cetyltrimethylammonium salt.
18. A method according to claim 1, in which the cationic detergent is cetyltrimethylammonium bromide.
19. A method according to claim 1, in which the cationic detergent is a stearyldimethylbenzylammonium salt.
20. A method according to claim 1, in which the cationic detergent is a cetylpyridinium salt.
21. A method according to claim 1, in which the cationic detergent is a benzalkonium chloride or bromide.
22. A method according to claim 1, in which the cationic detergent is benzethonium or methylbenzethonium chloride.
23. A method according to claim 1, in which the cationic detergent is decamethonium chloride.
US05/687,453 1974-01-14 1976-05-18 Process for isolating the immunogenic components of influenza viruses Expired - Lifetime US4064232A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/836,015 US4140762A (en) 1974-01-14 1977-09-23 Influenza sub-unit vaccine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH447/74 1974-01-14
CH44774A CH589453A5 (en) 1974-01-14 1974-01-14
US53934975A 1975-01-08 1975-01-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US53934975A Continuation 1974-01-14 1975-01-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US05/836,015 Division US4140762A (en) 1974-01-14 1977-09-23 Influenza sub-unit vaccine

Publications (1)

Publication Number Publication Date
US4064232A true US4064232A (en) 1977-12-20

Family

ID=25684599

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/687,453 Expired - Lifetime US4064232A (en) 1974-01-14 1976-05-18 Process for isolating the immunogenic components of influenza viruses

Country Status (1)

Country Link
US (1) US4064232A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206014A (en) * 1977-11-09 1980-06-03 Behringwerke Aktiengesellschaft Process for removing detergents from virus-antigen suspensions
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4344935A (en) * 1980-06-05 1982-08-17 Synthelabo Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines
US4356169A (en) * 1980-04-14 1982-10-26 Europaisches Laboratorium Fur Method of preparing an immunogenic membrane protein aggregate of influenza and parainfluenza viruses and rhabdoviruses
US4578269A (en) * 1982-10-18 1986-03-25 Bror Morein Immunogenic protein or peptide complex, method or producing said complex and the use thereof as an immune stimulant and as a vaccine
US6048537A (en) * 1994-08-16 2000-04-11 Pasteur Merieux Serums Et Vaccins Method for preparing an influenza virus, antigens obtained and applications thereof
US6656720B2 (en) 1996-04-01 2003-12-02 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses
WO2003097797A3 (en) * 2002-05-14 2004-02-19 Merck & Co Inc Methods of adenovirus purification
US20050118140A1 (en) * 2001-09-12 2005-06-02 Chiron Behring Gmbh & Co. Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
US20070117131A1 (en) * 1996-04-01 2007-05-24 Chiron Behring Gmbh & Co. Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
US20090304729A1 (en) * 2005-11-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US20230220356A1 (en) * 2019-11-07 2023-07-13 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blough--Virology, vol. 19, (1963), pp. 112-114. *
Bucher et al.--Chem. Abst., vol. 77, (1972), p. 71980v. *
hayman et al.--FEBS Letters, vol. 29, No. 2, (Jan. 1973), pp. 185-188. *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206014A (en) * 1977-11-09 1980-06-03 Behringwerke Aktiengesellschaft Process for removing detergents from virus-antigen suspensions
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4356169A (en) * 1980-04-14 1982-10-26 Europaisches Laboratorium Fur Method of preparing an immunogenic membrane protein aggregate of influenza and parainfluenza viruses and rhabdoviruses
US4344935A (en) * 1980-06-05 1982-08-17 Synthelabo Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines
US4578269A (en) * 1982-10-18 1986-03-25 Bror Morein Immunogenic protein or peptide complex, method or producing said complex and the use thereof as an immune stimulant and as a vaccine
US4744983A (en) * 1982-10-18 1988-05-17 Bror Morein Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
US6048537A (en) * 1994-08-16 2000-04-11 Pasteur Merieux Serums Et Vaccins Method for preparing an influenza virus, antigens obtained and applications thereof
US20050202553A1 (en) * 1996-04-01 2005-09-15 Chiron Behring Gmbh & Co Animal cells and processes for the replication of influenza viruses
US6656720B2 (en) 1996-04-01 2003-12-02 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses
US20070117131A1 (en) * 1996-04-01 2007-05-24 Chiron Behring Gmbh & Co. Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
US20080274141A1 (en) * 1996-04-01 2008-11-06 Novartis Vaccines And Diagnostics Gmbh & Co Kg Animal cells and processes for the replication of influenza viruses
US10329536B2 (en) 2001-09-12 2019-06-25 Seqirus UK Limited Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
US20050118140A1 (en) * 2001-09-12 2005-06-02 Chiron Behring Gmbh & Co. Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
US20050153420A1 (en) * 2002-05-14 2005-07-14 Konz Jr. John O. Methods of adenovirus purification
US20050196854A1 (en) * 2002-05-14 2005-09-08 Konz John O.Jr. Methods of adenovirus purification
US7326555B2 (en) 2002-05-14 2008-02-05 Merck & Co., Inc. Methods of adenovirus purification
WO2003097797A3 (en) * 2002-05-14 2004-02-19 Merck & Co Inc Methods of adenovirus purification
US20090304729A1 (en) * 2005-11-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna
US10655108B2 (en) * 2005-11-01 2020-05-19 Seqirus UK Limited Cell-derived viral vaccines with low levels of residual cell DNA
US11466257B2 (en) 2005-11-01 2022-10-11 Seqirus UK Limited Cell-derived viral vaccines with low levels of residual cell DNA
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US10946088B2 (en) 2008-03-18 2021-03-16 Seqirus UK Limited Preparation of influenza virus vaccine antigens
US12318442B2 (en) 2008-03-18 2025-06-03 Seqirus UK Limited Preparation of influenza virus vaccine antigens
US20230220356A1 (en) * 2019-11-07 2023-07-13 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size

Similar Documents

Publication Publication Date Title
US4064232A (en) Process for isolating the immunogenic components of influenza viruses
Enami et al. High-efficiency formation of influenza virus transfectants
JP5258127B2 (en) Influenza vaccine
Yap et al. The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes
US3962421A (en) Method for the disruption of lipid-containing viruses
AU701024B2 (en) Method for preparing an influenza virus, antigens obtained and applications thereof
Justewicz et al. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin
US4140762A (en) Influenza sub-unit vaccine
JP2000507825A (en) Method of influenza virus replication in cell culture, and influenza virus obtainable by the method
Rytel et al. The Influence of Cortisone on Experimental Viral Infection: VIII. Suppression by Cortisone of Interferon Formation in Mice Injected With Newcastle Disease Virus
FI73596B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT VACCIN AV HERPES SIMPLEX TYP 1.
JP2001504496A (en) Immunization of infants
CA1049406A (en) Isolation of hemagglutinin and neuraminidase from influenza virus
US3892627A (en) Feline panleukopenia vaccine
Doherty et al. Recombinant vaccinia viruses and the development of immunization strategies using influenza virus
Hocart et al. Preparation and characterization of a purified influenza virus neuraminidase vaccine
EP0135435A2 (en) Immunogenic HBsAg derived from transformed yeast
DE2829089A1 (en) SUBUNIT VACCINE
Reiss et al. Specificity of the helper T cell for the cytolytic T lymphocyte response to influenza viruses
EP0084953A1 (en) Interferon induction method
US2506345A (en) Method of separating live viruses from nonviral protein matter
Mifune et al. A mouse model for the pathogenesis and postexposure prophylaxis of rabies
KR790001144B1 (en) Method of Making Influenza Vaccine
CA1270438A (en) Influenza vaccine
US11890338B2 (en) Inactivated whole-virus influenza vaccine and method for preparing same

Legal Events

Date Code Title Description
AS Assignment

Owner name: DUPHAR B.V.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:FIDELITY UNION BANK;REEL/FRAME:004150/0162

Effective date: 19830602